

Email: PMPRB.Consultations.CEPMB@pmprb-cepmb.gc.ca

August 4, 2020

Dr. Mitch Levine Chair, Patented Medicine Prices Review Board 333 Laurier Street, Suite 1400 Ottawa, ON K1P 1C1

Dear Dr. Levine:

On behalf of Ipsen Biopharmaceuticals Canada Inc., we concur and agree with the comments brought forth by Innovative Medicines Canada with regards to the proposed changes to the PMPRB guidelines and strongly believe that the guidelines as currently proposed will have a significant and negative impact on patient access to new medicines in Canada.

Thank you for the time and opportunity to provide input in the PMPRB consultation process.

Sincerely,

Christine Mossa HBSc., PMP, RAC

Director, Regulatory Affairs, Reimbursement & Value Access

Phone: (416) 475-9909 Fax: (289) 724-3415

Ipsen Biopharmaceuticals Canada Inc.

5060 Spectrum Way, 5th Floor Mississauga, ON L4W 5N5 Canada

